Full Text View
Tabular View
No Study Results Posted
Related Studies
Characteristics and Disease Progression of Mixed Connective Tissue Disease and Systemic Lupus Erythematosus
This study is currently recruiting participants.
Study NCT00582881   Information provided by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
First Received: December 19, 2007   Last Updated: March 31, 2009   History of Changes

December 19, 2007
March 31, 2009
October 2007
September 2012   (final data collection date for primary outcome measure)
  • Data characterizing CD4 T cells and corresponding clinical data [ Time Frame: Every 3 months ] [ Designated as safety issue: No ]
  • Phenotype measurement to include disease activity, disease severity, and functional status [ Time Frame: Every 3 months ] [ Designated as safety issue: No ]
  • Data characterizing CD4 T cells and corresponding clinical data [ Time Frame: At every 3 months ] [ Designated as safety issue: No ]
  • Phenotype measurement to include disease activity, disease severity, and functional status [ Time Frame: At every 3 months ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00582881 on ClinicalTrials.gov Archive Site
 
 
 
Characteristics and Disease Progression of Mixed Connective Tissue Disease and Systemic Lupus Erythematosus
Immune Response to Small Nuclear Ribonucleoprotein Autoantigens

Systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD) are long-term autoimmune diseases in which the immune system attacks parts of the body. The abnormal immune reaction causes inflammation of and damage to various body parts and can affect joints, skin, kidneys, heart, lungs, blood vessels, and the brain. SLE and MCTD often affect young women, especially black and Hispanic women, and there is no known cure. Knowing more about SLE and MCTD will help in developing new and effective treatments. The purpose of this study is to characterize immune system abnormalities, genetic components, and disease progression in people with SLE and MCTD.

Systemic lupus erythematosus (SLE) is an autoimmune disease in which the immune system produces antibodies against the body's healthy cells and tissues. These antibodies, called autoantibodies, contribute to the inflammation of various parts of the body and can cause damage to organs and tissues. Mixed connective tissue disease (MCTD) is another autoimmune disease that overlaps in terms of signs and symptoms with three other connective tissue diseases, including SLE. In both SLE and MCTD, the immune system appears to be abnormally activated by small nuclear ribonucleoprotein (snRNP) autoantigens. Furthermore, lung tissue, in particular, appears to be affected by the immune response induced by snRNP autoantigens. The causes of SLE and MCTD remain unknown. However, it is likely that a combination of genetic, environmental, and possibly hormonal factors work together to cause the diseases. Past studies suggest that several different genes may be involved in determining a person's likelihood of developing SLE or MCTD, which tissues and organs are affected, and the severity of the disease. The purpose of this study is to characterize immune system abnormalities, genetic components, and disease progression in people with SLE and MCTD.

Participants will attend at least four study visits, spaced 3 months apart, over the course of this study. Each study visit will include questionnaires, a physical exam, and possibly blood and/or urine collection. At the end of the study period, participants may choose to continue or discontinue participation.

 
Observational
Cohort, Cross-Sectional
  • Mixed Connective Tissue Disease
  • Systemic Lupus Erythematosus
 
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
400
September 2012
September 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Presence of anti-RNP or anti-Sm antibodies

Exclusion Criteria:

  • Lacking at least two criteria for MCTD or two criteria for SLE after the 1-year follow-up visit
Both
16 Years and older
No
Contact: Judith Pignac-Kobinger, MS 305-243-8567 jpignac@med.miami.edu
Contact: Robert W. Hoffman, DO 305-243-6866 rhoffman@med.miami.edu
United States
 
NCT00582881
Robert W. Hoffman, University of Miami Miller School of Medicine
R01 AR043308, 2R01 AR 043308-12A1
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
 
Principal Investigator: Robert W. Hoffman, DO University of Miami Miller School of Medicine
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
March 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP